Targeting Glioblastoma Stem Cells: Cell Surface Markers

$63.00 plus tax (Refund Policy)

Buy Article:

Abstract:

Glioblastoma multiforme (GBM) is the most common primary brain tumor and among the most lethal cancers. There is increasing evidence that cancer stem cells within GBMs, which are often referred to as glioblastoma stem cells (GSCs), play a critical role in tumor initiation and maintenance. Identification of novel markers for GSCs will lead to better targeting of GSCs which could have tremendous impact on treatment of GBMs. Cell surface markers are particularly suitable as therapeutic targets. Although several promising cell surface markers have successfully been used for enrichment of GSCs, their functional roles in maintenance of GSC properties as well as in GBM formation and development remain to be characterized. In this review, we primarily summarize recent advances in identification of GSC markers, with a particular focus on cell surface markers.

Keywords: Glioblastoma stem cell; cell surface markers; proteomics; therapeutic target

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/092986712804485944

Publication date: December 1, 2012

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more